TIDMPOLX

RNS Number : 7681G

Polarean Imaging PLC

25 July 2019

Polarean Imaging Plc

("Polarean" or the "Company")

Result of AGM

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.

Enquiries:

 
 Polarean Imaging plc                               www.polarean.com / www.polarean-ir.com 
 Richard Hullihen, Chief Executive Officer                                 Via Walbrook PR 
 Richard Morgan, Chairman 
  Chuck Osborne, Chief Financial Officer 
 
 SP Angel Corporate Finance LLP                                   Tel: +44 (0)20 3470 0470 
 David Hignell / Lindsay Mair / Jamie Spotswood 
  (Corporate Finance) 
  Vadim Alexandre / Rob Rees (Corporate Broking) 
 
 Walbrook PR                           Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com 
 Paul McManus / Anna Dunphy                         Mob: +44 (0)7980 541 893 / +44 (0)7879 
                                                                                   741 001

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution functional magnetic resonance imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas ((129) Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate than current methods. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGSEAFLIFUSEEW

(END) Dow Jones Newswires

July 25, 2019 10:31 ET (14:31 GMT)

Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Polarean Imaging.
Polarean Imaging (LSE:POLX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Polarean Imaging.